Leukemia News

SAN DIEGO — Researchers reported encouraging early results from novel therapies targeting menin in patients with relapsed or refractory acute leukemias harboring specific genetic alterations.

SAN DIEGO — In this video, Catherine Lai, MD, MPH, discusses the results from the Augment-101 phase 2 study presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Catherine Lai, MD, MPH, spoke with Healio about a study assessing an all-oral regimen that included arsenic for patients with high-risk acute promyelocytic leukemia, a subset of acute myeloid leukemia.

SAN DIEGO — In this video, Catherine Lai, MD, MPH, highlights early phase studies presented at ASH Annual Meeting and Exposition that investigated triplet therapy in acute myeloid leukemia.

SAN DIEGO — In this video, Catherine Lai, MD, MPH, spoke with Healio about patients with newly diagnosed or relapsed acute myeloid leukemia who stopped treatment with azacitidine/venetoclax after receiving one or more cycles past remission.

Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.

SAN DIEGO — Personalizing treatment using both geriatric assessment and genetic profiling may decrease rates of early mortality among older patients with acute myeloid leukemia, according to a study from ASH Annual Meeting and Exposition.

This year’s ASH Annual Meeting featured several high-impact abstracts.

In this video, Akriti Jain, MD, discusses whether patients with acute myeloid leukemia with IDH mutations should be treated with IDH inhibitors up front compared to venetoclaxcontaining regimens.

In this video, Eunice Wang, MD discusses acute myeloid leukemia highlights from the ASH Annual Meeting and Exposition.